Key Takeaways
- Eli Lilly reports that Foundayo demonstrates superior performance compared to Novo Nordisk’s oral Ozempic in type 2 diabetes treatment.
- The 17.2 mg Foundayo dose achieved approximately 2% greater weight reduction versus the 25 mg Ozempic pill formulation.
- The high-dose oral Ozempic pill currently lacks FDA approval for type 2 diabetes in the United States, with regulatory decision anticipated by late 2026.
- In separate findings, Lilly demonstrated that elevated Zepbound doses surpass Novo’s Wegovy HD in weight management outcomes.
- Zepbound 15 mg users experienced approximately 5% additional weight loss compared to Wegovy HD participants.
Eli Lilly has intensified its competitive positioning in the obesity and diabetes treatment space with new comparative analyses pitting its medications against Novo Nordisk’s competing products. The pharmaceutical giant published fresh clinical evidence this week highlighting performance advantages.
Earlier this week, the Indianapolis-based drugmaker announced that Foundayo demonstrates superior efficacy versus Novo’s oral Ozempic formulation in adult patients managing type 2 diabetes. The assertion stems from indirect statistical comparisons rather than direct clinical trials.
The pharmaceutical company analyzed results from two distinct late-stage clinical investigations to establish the comparison framework. Researchers evaluated Foundayo at 17.2 mg dosing versus Novo’s 25 mg oral semaglutide tablet.
The findings indicated that Foundayo produced approximately 2% superior weight reduction outcomes compared to the higher-dose Ozempic tablet formulation. Additionally, Lilly documented marginally enhanced glycemic control metrics in the identical analytical framework.
Currently, Novo’s 25 mg oral Ozempic tablet lacks regulatory clearance in the United States for type 2 diabetes treatment. Federal regulators are projected to issue their determination before 2026 concludes.
Novo Nordisk Responds
Novo Nordisk quickly countered Lilly’s comparative claims. A company representative informed Reuters that the analysis centered on type 2 diabetes patients rather than obesity-focused populations.
This differentiation carries significant weight. Clinical evidence consistently shows that diabetic patients typically achieve more modest weight reduction outcomes compared to individuals receiving treatment exclusively for obesity management.
Both Ozempic’s tablet formulation and Foundayo fall within the GLP-1 receptor agonist therapeutic category. These pharmaceutical interventions function by modulating glucose metabolism and reducing hunger signals.
Zepbound Versus Wegovy HD Comparison
The pharmaceutical company extended its comparative analysis beyond diabetes management. Lilly unveiled additional evidence examining its Zepbound injection against Novo’s elevated-dose Wegovy formulation.
The evaluation assessed Zepbound at both 10 mg and 15 mg dosing levels against Wegovy HD throughout a 72-week treatment period. These represent prominent injectable therapies for obesity management.
Participants receiving Zepbound 15 mg demonstrated approximately 5% superior average body weight reduction compared to Wegovy HD recipients. The 10 mg dosing cohort achieved roughly 3% additional weight loss.
According to Lilly’s analysis, patients administered the 15 mg dose were three times more probable to achieve 20% or greater weight reduction compared to Wegovy HD users. Treatment discontinuation frequencies due to adverse reactions remained comparable across all evaluated groups.
The comparative evidence originated from Lilly’s SURMOUNT-1 investigation and Novo’s STEP UP research programs. Both clinical trials recruited thousands of participants with elevated body weight or obesity across international locations.
Lilly unveiled these findings during the European Association for the Study of Diabetes annual scientific conference. Rachel Batterham, serving as Lilly’s senior vice president of medical innovation, acknowledged that direct comparative trials provide optimal evidence quality, though indirect analyses can supply valuable insights when head-to-head studies haven’t been conducted.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
